Monitor ASN Kidney Week 2026 for the late-breaking poster data on izicopan in kidney disease models; any positive preclinical results could support the renal indication strategy but are unlikely to move the stock materially without Phase 2/3 clinical data.
Price Chart
Executive Summary
InflaRx announced that its oral C5aR1 antagonist izicopan was selected for a late-breaking poster at ASN Kidney Week 2026, presenting preclinical kidney disease model data. The abstract highlights izicopan's favorable PK/PD profile, lack of CYP3A4 time-dependent inhibition, and promising Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, supporting its development in ANCA-associated vasculitis and renal indications. This is a routine scientific conference presentation with no new clinical data or regulatory catalyst disclosed.
Key Facts
- Izicopan selected for late-breaking poster at ASN Kidney Week 2026 (Oct 22, 2026, Denver, CO)
- Poster title: 'Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models'
- Izicopan does not exhibit time-dependent inhibition of CYP3A4 in vitro, unlike the marketed C5aR inhibitor
- Phase 1 data showed ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing
- Phase 2a data in hidradenitis suppurativa showed rapid reductions in abscesses/nodules and draining tunnels, with deepening HiSCR responses 4 weeks post-treatment
- Phase 2a data in chronic spontaneous urticaria showed substantial reductions in UAS7 and improved UCT7 scores
- Company planning development of izicopan in ANCA-associated vasculitis and additional renal indications
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech
Risk Factors
- Preclinical kidney disease model data may not translate to clinical efficacy in ANCA-associated vasculitis or other renal indications
- No new clinical data or regulatory milestone announced; conference presentation is routine and unlikely to drive near-term stock movement
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373754 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers